The Federal Trade Commission today announced 11 law enforcement actions challenging deceptive advertising of bogus cancer cures. The FTC charged the companies with making unsupported claims that their products cured or treated one or more types of cancer. In each case, the company is charged with violating the FTC Act, which bars deceptive claims. Some […]
Monthly Archives: September 2008
FTC Sweep Stops Peddlers of Bogus Cancer Cures
The Federal Trade Commission today announced 11 law enforcement actions challenging deceptive advertising of bogus cancer cures. The FTC charged the companies with making unsupported claims that their products cured or treated one or more types of cancer. In each case, the company is charged with violating the FTC Act, which bars deceptive claims. Some […]
FTCs Operation False Cures Targets Peddlers of Bogus Cancer Remedies
WHO: Lydia Parnes, Director, FTC Bureau of Consumer Protection Douglas Stearn, Director, Division of Compliance Policy, Office of Enforcement, U.S. Food and Drug Administration WHERE: Federal Trade Commission 600 Pennsylvania Ave., N.W., Room 432Washington, DC Call-in Information: The toll-free phone number (in the U.S. and Canada) is 866-363-9013. The confirmation number is 65145274. Please reference […]
FTC Challenges Reed Elsevier’s Proposed $4.1 Billion Acquisition of ChoicePoint, Inc.
The Federal Trade Commission today issued a complaint charging that Reed Elsevier Inc.’s (Reed Elsevier) proposed $4.1 billion acquisition of ChoicePoint Inc. (ChoicePoint) would be anticompetitive and in violation of the antitrust laws, as it would combine the two largest providers of electronic public record services to U.S. law enforcement customers. To eliminate the anticompetitive […]
FTC Challenges Reed Elsevier’s Proposed $4.1 Billion Acquisition of ChoicePoint, Inc.
The Federal Trade Commission today issued a complaint charging that Reed Elsevier Inc.’s (Reed Elsevier) proposed $4.1 billion acquisition of ChoicePoint Inc. (ChoicePoint) would be anticompetitive and in violation of the antitrust laws, as it would combine the two largest providers of electronic public record services to U.S. law enforcement customers. To eliminate the anticompetitive […]
FTC Testifies on Deceptive Marketing of Prepaid Phone Cards
The Federal Trade Commission today told the U.S. House Subcommittee on Commerce, Trade and Consumer Protection of the Committee on Energy and Commerce that the FTC would continue to take aggressive steps to combat the deceptive marketing of prepaid phone cards, and that pending legislation would benefit consumers by providing “an additional remedy to those […]
FTC Testifies on Deceptive Marketing of Prepaid Phone Cards
The Federal Trade Commission today told the U.S. House Subcommittee on Commerce, Trade and Consumer Protection of the Committee on Energy and Commerce that the FTC would continue to take aggressive steps to combat the deceptive marketing of prepaid phone cards, and that pending legislation would benefit consumers by providing “an additional remedy to those […]
FTC Receives Application for Approval of Proposed Divestiture from Chicago Bridge & Iron Company; Commission Approves Final Consent Order in the Matter of McCormick & Company and Unilever Group
Application for approval of proposed divestiture – The Commission has received an application for approval of a proposed divestiture from Chicago Bridge & Iron Company N.V. and Chicago Bridge & Iron Company (collectively CB&I). The application was filed in connection with the matter entitled In the Matter of Chicago Bridge & Iron Company N.V. et […]
FTC Challenges Vertical Agreement Between Fresenius and Daiichi Sankyo
The Federal Trade Commission today announced a complaint challenging Fresenius Medical Care Ag & Co. KGaA’s (Fresenius) proposed acquisition of an exclusive sublicense from Luitpold Pharmaceuticals, Inc. (Luitpold), a wholly owned U.S. subsidiary of the Japanese firm Daiichi Sankyo Company, Ltd. Under the sublicense, Fresenius would manufacture and supply the intravenous iron drug Venofer to […]
FTC Challenges Vertical Agreement Between Fresenius and Daiichi Sankyo
The Federal Trade Commission today announced a complaint challenging Fresenius Medical Care Ag & Co. KGaA’s (Fresenius) proposed acquisition of an exclusive sublicense from Luitpold Pharmaceuticals, Inc. (Luitpold), a wholly owned U.S. subsidiary of the Japanese firm Daiichi Sankyo Company, Ltd. Under the sublicense, Fresenius would manufacture and supply the intravenous iron drug Venofer to […]